Loading…
← CockpitCompetitor Analysis › 3151.T Vital KSK Holdings, Inc.Open in the cockpit ↗

Vital KSK Holdings, Inc.3151.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Distributors
Momentum weak 36
Mkt cap
$399M
US dollars, full cap
Free float
63%
of shares outstanding
$/day
$1.23M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-3.2 pp
WACC 5.2%
Hurdle
+2 pp
Req g minus delivered
Next earnings
78 days
4 Feb 2027
Close · JPY¥1,421
1D-0.8%
1W+4.0%
1M-7.8%
3M-12.0%
6M-1.4%
YTD+3.7%
1Y+13.6%
ATR %3.0%
52w lowhigh17.7% off high

What Vital KSK does

Employees: 3,871

Vital KSK at a glance

Size Vital KSK (3151.T) is a Japan Health Care company (Medical Distributors) with a market value of $399M, the 1182nd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,421 on 18 Nov 2026.

Performance Over six months the shares fell 1.4%, against -5.6% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 2.7% over the last twelve months (peer median +3.9%); the operating margin is 0.5% (peer median 2.3%).

Valuation It trades at 0.1× enterprise value to sales against a peer median of 1.2× (cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.2 points below its cost of capital (5.2% WACC).

Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).

Relative performance

10011021 May 202621 Aug 202618 Nov 20263151.T 96Peer median 95
Six months, rebased to 100: Vital KSK against the median of its 20 peers (local-currency closes).

Vital KSK financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥620B¥610B¥600B¥587B¥581B
Revenue growth—+2%+2%+1%—
Gross profit¥50.1B¥49.6B¥49.2B¥48.3B¥46.5B
EBITDA¥7.32B¥8.08B¥9.49B¥8.84B¥7.38B
Net income¥2.86B¥7.36B¥7.31B¥5.84B¥4.83B
Free cash flown/a¥1.11B-¥10.6B¥21.7B-¥8.84B
Capital expendituren/a¥5.27B¥4.34B¥5.10B¥6.60B
Total debt¥8.74B¥7.29B¥7.70B¥10.2B¥10.9B

Quarterly statements and history in the cockpit →

Vital KSK competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%0%+20%410400007866176037166051363011667447301370000668600628688366ENTEROARJO-B603368DOCM74763151.T6-month return →1-month return →
Up and to the right = strong over both horizons. Vital KSK is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×2×4×4104000078661760371660513630116674473013700006686006282733NEU688366ENTEROARJO-B6033683015843151.TRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Vital KSK is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%41040000786051367447301370000668600628NEU688366ENTERO6033683015843151.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Vital KSK is the large dot.

Vital KSK competitors and peer comparison

How Vital KSK compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Vital KSK against its 20 peers (data as of 18 Nov 2026)
Measure3151.TPeer medianRank in peer set
1-month return-7.8%-3.7%7th lowest of 21
6-month return-1.4%-5.6%9th highest of 21
Distance from 52-week high-17.7%-22.4%8th highest of 21
Revenue growth (TTM)+2.7%+3.9%10th lowest of 21
Operating margin0.5%2.3%7th lowest of 21
EV / Sales0.1×1.2×cheapest of 21
Growth the price implies (Req g, 7 yrs)4.7%0.0%8th most demanding of 16
Growth delivered (Del g)+2.6%+6.0%5th lowest of 16
Hurdle (Req g minus delivered)+2.1 pp-5.3 pp5th most demanding of 16
ROIC minus cost of capital-3.2 pp-0.2 pp9th lowest of 21
Net debt / EBITDA-1.7×1.5×3rd least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Vital KSK 3151.TJapan$399M-1%+3%0%0.1×4.7%+2.6%
Excelsior Medical 4104.TWTaiwan$404M+5%+11%8%1.4×-1.2%+5.7%
Shenzhen Neptunus Bioengineering 000078.SZChina$411M-48%-22%-1%0.6×58.3%-7.8%
Gongwin Biopharm 6617.TWOTaiwan$412M+87%+12%-530%288.8×n/an/a
Thalys Medical Technology 603716.SSChina$446M-33%-43%-18%4.3×n/an/a
Shanghai Lily & Beauty Cosmetics 605136.SSChina$449M-28%+5%2%1.1×21.1%-18.1%
Shanghai Universal Biotech 301166.SZChina$337M-15%+15%-4%1.0×n/an/a
Nagaileben 7447.TJapan$319M0%+1%21%1.6×-12.7%-0.4%
GKHT Medical Technology 301370.SZChina$525M-24%-11%1%0.7×13.1%+7.5%
Rongfeng 000668.SZChina$297M-32%+61%14%4.8×9.6%+30.0%
Shanghai New World 600628.SSChina$573M-10%-2%6%2.1×-1.6%+1.0%
Arata 2733.TJapan$576M-3%+3%1%0.1×-6.2%+3.8%
Neuca NEU.WAPoland$795M-9%+8%2%0.3×5.3%+8.1%
Shanghai Haohai Biological Technology 688366.SSChina$878M-24%-9%-2%1.8×16.9%+13.2%
Entero Healthcare Solutions ENTERO.NSIndia$925M+60%+35%4%1.2×24.7%+29.9%
Arjo ARJO-B.STSweden$974M+42%0%8%1.3×-1.0%+3.9%
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%0.4×-9.7%+6.0%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%0.3×n/an/a
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%0.5×-2.7%+17.9%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%1.0×n/an/a
AS ONE 7476.TJapan$1.10B+25%+10%12%1.3×0.0%+6.3%

Questions

Which companies are Vital KSK's closest peers?
The cockpit's peer set: Excelsior Medical (4104.TW), Shenzhen Neptunus Bioengineering (000078.SZ), Gongwin Biopharm (6617.TWO), Thalys Medical Technology (603716.SS), Shanghai Lily & Beauty Cosmetics (605136.SS), Shanghai Universal Biotech (301166.SZ), Nagaileben (7447.T), GKHT Medical Technology (301370.SZ).
Is Vital KSK expensive compared with its peers?
On ev / sales it trades at 0.1× against a peer median of 1.2×, cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Vital KSK stock performed?
Over six months to 18 Nov 2026 the shares returned -1.4% against -5.6% for the median peer; over one year +13.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.